Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	A key decision on compounding is expected this week - 8 days ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 7 months ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	3 closely watched drugs that failed in the clinic - 10 days ago The big rebrand: Why these 4 biopharmas changed their name this year - 22 days ago 2024 PharmaVoice 100s: Rare Disease Warriors - about 2 months ago 2024 PharmaVoice 100s: Trailblazers - 2 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 3 months ago What 3 layoff stories reveal about pharma’s troubles - 4 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 7 months ago Where competition is heating up in pharma - 7 months ago The biggest questions hanging over pharma in 2024 - 11 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 12 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 12 months ago 10 of our most read articles in 2023 - about 1 year ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - about 1 year ago PharmaVoice 100s: Entrepreneurs - about 1 year ago PharmaVoice 100s: Clinical trial gurus - about 1 year ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - about 2 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 9 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 10 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - about 1 year ago
4	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 2 months ago
5	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 2 months ago
6	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 2 months ago
7	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech news roundup to start your week - about 2 months ago The biotech news you need to read today - about 2 months ago Is pharma still fearful of the Inflation Reduction Act? - 4 months ago The biotech news you missed this week - 6 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 7 months ago The Senate health committee looks into its first subpoena in 40 years - 11 months ago The biotech updates you need to read today - about 1 year ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - about 1 year ago FDA chastens pet companies over antibiotics - about 1 year ago The biotech news you missed from the weekend - about 1 year ago Novartis is building a new radioligand plant in China - about 1 year ago Johnson & Johnson bets heavy on AI-driven drug discovery - about 1 year ago Today’s biotech news roundup, in under 800 words - about 1 year ago A new algorithm unveils CRISPR ‘treasure trove’ - about 1 year ago These are the need-to-know biotech stories from this weekend - about 1 year ago Your Monday morning biotech news roundup - about 1 year ago Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO - about 1 year ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - about 1 year ago
8	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	The biotech updates you need to read this morning - 2 months ago
9	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 4 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 7 months ago 4 offbeat biotechs making a splash in the life sciences - 8 months ago How a biotech exec is leveraging Big Pharma lessons to advance tRNA - 8 months ago
10	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	A biotech’s binary bet ends badly - 6 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 7 months ago

Journalists covering biopharma journalism